Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Developing Guidance On Rational Development Of Combined Novel Drugs

Executive Summary

FDA is developing guidances -both in general and for specific therapeutic areas - for co-development of investigational drugs intended to be used in combination, and the move is indeed timely.

You may also be interested in...



FDA Draft Co-Development Guidance Emphasizes Phase II Studies

Clinical trial strategies proposed in FDA's draft guidance for co-development of drugs designed for use in combination in most cases whittle the design down to standard of care versus the combination before Phase III, offering the prospect of cutting not only development time but also clinical trial costs.

FDA Draft Co-Development Guidance Emphasizes Phase II Studies

Clinical trial strategies proposed in FDA's draft guidance for co-development of drugs designed for use in combination in most cases whittle the design down to standard of care versus the combination before Phase III, offering the prospect of cutting not only development time but also clinical trial costs.

FDA Issues Co-Development Guidance, But Only For Products Treating "Serious" Diseases

FDA Commissioner Hamburg and CDER Director Woodcock outline the requirements for developing drugs in combination during the Faster Cures Partnering for Cures meeting in New York.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel